Volume 20, Number 1—January 2014
Dispatch
Increasing Threat of Brucellosis to Low-Risk Persons in Urban Settings, China
Table 1
Clinical and laboratory data on twin patients on admission to the infectious disease hospital
Variables* | Patient 1, twin boy | Patient 2, twin girl | Reference range (children)† |
---|---|---|---|
Temperature, °C | 38 | 37.0 | 36–37 |
Pulse, beats/min | 128 | 128b | 120 |
Respiratory rate, breaths/min | 34 | 36 | 30–35 |
Blood pressure, mmHg | 76/42 | 76/45 | 80/48 |
Weight, kg | 5.7 | 5.6 | |
Erythrocyte count, cells/L | 4.99 × 1012 | 4.69 × 1012 | 3.5–5.5 × 1012 |
Hemoglobin, g/L | 85 | 89 | 120–160 |
Hematocrit, % | 26.3 | 27.5 | 40–50 |
Erythrocyte sedimentation rate, mm/h | 5 | No record | <10 |
Leukocyte count, cells/L | 7 × 109 | 8.51 × 109 | 4.0–10.0 × 109 |
Differential count, % | |||
Neutrophils | 18.8 | 10.7 | 50–75 |
Eosnophils | 3 | 1.1 | 0.5–5 |
Basophiles | 0.2 | 0.3 | 0–1.0 |
Lymphocytes | 74.3 | 83.9 | 20–40 |
Monocytes | 3.7 | 4 | 3.0–10.0 |
Platelet count, per L | 462 × 109 | 456 × 109 | 100–300 × 109 |
Sodium, mmol/L | 103 | 135.4 | 135–145 |
Potassium, mmol/L | 33 | No record | 3.4–4.8 |
Glucose 6-dehydrogenase, U/L | 4,254 | 1,363 | ≥2,500 |
Lactate dehydrogenase, U/L | 356 | 322 | 100–380 |
Alanine aminotransferase, U/L | 31 | 48 | 5–40 |
Aspartate aminotransferase, U/L | 54 | 64 | 5–40 |
Alkaline phosphatase, U/L | 508 | 642 | 30–390 |
Total bilirubin, µmol/L | 8.49 | 5.17 | 5.10–22.2 |
Total protein, g/L | 51 | 49 | 60–68 |
Albumin, g/L | 37 | 40 | 35–55 |
Globulin, g/L | 14 | 9 | 20–35 |
C-reactive protein, mg/L | 0.2 | 0.21 | 0.03–5 |
Creatine kinase, U/L | 49 | 203 | 24–194 |
Creatine kinase-MB, U/L | 32 | 25 | 0–25 |
Brucella antibody titer, SAT | 400 | 800 | <100 |
Blood culture | B. melitensis | B. melitensis | |
Hepatitis B surface antigen | Negative | Negative | |
Antibody to hepatitis B surface antigen, IU/L | 6.77 | Negative | |
Hepatitis B e antigen | Negative | Negative | |
EBV IgA | Negative | Negative | |
Cytomegalovirus IgM | Negative | Negative | |
Herpes simplex virus 1, 2 IgM | Negative | Negative | |
Influenza virus A + B antigens | Negative | Negative | |
Mycoplasma IgM | Negative | Negative | |
Chlamydia pneumoniae IgM | Negative | Negative | |
Toxoplasma IgM | Negative | Negative |
[[tablefoot]]
1These authors contributed equally to this article.
Page created: December 18, 2013
Page updated: December 18, 2013
Page reviewed: December 18, 2013
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.